1.Biomechanical Effects of Jumping Distance on Stress Distributions of Anterior Dental Implant with Socket-Shield Technique
Qian WANG ; Jingheng SHU ; Tinghui SUN ; Haidong TENG ; Bingme SHAO ; Zhan LIU
Journal of Medical Biomechanics 2023;38(3):E594-E600
Objective To study the biomechanical effect of jumping distance on dental implants with socket-shield technique (SST), so as to provide references for clinical standards of jump distance. Methods Based on clinical characteristics, four groups of three-dimensional (3D) SST implant system models with 0, 0. 5, 1 and 1. 5 mm jumping distance were established, and the corresponding material parameters were assigned. The peak stress and stress distributions on models were simulated under specific occlusal condition. Results When the jumpingdistance was non-zero, namely, the implant was not in contact with the retained root fragment, the stress of the implant and abutment increased with the increase of jumping distance, and the peak stress in root fragment and periodontal membrane decreased with the increase of jumping distance. When the jumping distance was zero, the peak stress of the implant, abutment, root fragment and periodontal membrane reached the maximum, far exceeding that of the other groups. Conclusions The jumping distance has a significant effect on the SST implant system. It is recommended to take a larger jumping distance in clinical practices. The edge of the root fragment should be rounded, and the size of the lower edge should not be too small.
2.Vaccination in patients with inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Su Bum PARK ; Kyeong Ok KIM ; Hong Sub LEE ; Chang Hwan CHOI ; Shu Chen WEI ; Min Hu CHEN ; Katsuyoshi MATSUOKA
Intestinal Research 2023;21(3):363-374
Background/Aims:
Long-term immunosuppressive therapies used to treat inflammatory bowel disease (IBD) are associated with an increased risk of infections, many of which can be prevented by vaccination. We assessed physicians’ current approaches and clinical practices regarding vaccinations for IBD patients in different Asian countries/regions.
Methods:
An internet-based survey was conducted among members of the Asian Organization for Crohn’s and Colitis from September 2020 to November 2020. The questionnaire consisted of 2 parts covering general opinion on the relevance of vaccinations and clinical practice of vaccination.
Results:
Overall, 384 Asian medical doctors responded to the survey. The majority of respondents considered it very (57.6%) or sufficiently (39.6%) important to perform vaccinations as recommended by the guidelines. About half of the Asian physicians (52.6%) were usually or always performing vaccinations. The influenza vaccine was the most frequently recommended vaccine for IBD patients. Half of the respondents (51.3%) did not recommend hepatitis A vaccine, especially in China (61.6%) and Japan (93.6%). The diphtheria, tetanus, and pertussis vaccine were never (35.2%) or rarely (29.4%) recommended.
Conclusions
The findings of this survey indicated similarities among countries/regions in terms of the current approaches and practices regarding vaccination of IBD patients; however, there are some differences that might reflect each country’s domestic vaccination guidelines and health insurance particularly with certain vaccines in some countries/regions. Although Asian physicians largely recommend vaccination, more awareness among doctors and Asian consensus regarding differences in IBD vaccination among countries/regions may be required.
3.Prescription Patterns for Bipolar Disorder in Asian Countries:Findings from Research on Asian Prescription Pattern-Bipolar Disorder
Shih-Ku LIN ; Shu-Yu YANG ; Seon-Cheol PARK ; Ok-Jin JANG ; Xiaomin ZHU ; Yu-Tao XIANG ; Wen-Chen OUYANG ; Afzal JAVED ; M. Nasar SAYEED KHAN ; Sandeep GROVER ; Ajit AVASTHI ; Roy Abraham KALLIVAYALIL ; Kok Yoon CHEE ; Norliza CHEMI ; Takahiro A. KATO ; Kohei HAYAKAWA ; Pornjira PARIWATCHARAKUL ; Margarita MARAMIS ; Lakmi SENEVIRATNE ; Sim KANG ; Wai Kwong TANG ; Tin OO ; Norman SARTORIUS ; Chay-Hoon TAN ; Mian-Yoon CHONG ; Yong Chon PARK ; Naotaka SHINFUKU
Clinical Psychopharmacology and Neuroscience 2022;20(1):61-69
Objective:
Pharmacotherapy including mood stabilizers and antipsychotics are frequently used in bipolar disorder (BD); however, the lack of consensus regarding the definition of polypharmacy hinders conducting comparative studies across different settings and countries. Research on Asian Prescription Pattern (REAP) is the largest and the longest lasting international collaborative research in psychiatry in Asia. The objective of REAP BD was to investigate the prescription patterns of psychotropic medications across Asian countries. The rates of polypharmacy and psychotropic drug load were also analyzed.
Methods:
The data collection was web-based. Prescription patterns were categorized as (1) mood stabilizer monotherapy: one mood stabilizer; (2) antipsychotic monotherapy: one antipsychotic; (3) simple polypharmacy: one mood stabilizer and one antipsychotic; and (4) complex polypharmacy: ≥ 2 mood stabilizers or/and antipsychotics. The psychotropic drug load in each patient was calculated using the defined daily dose method.
Results:
Among 2003 patients with BD (52.1% female, 42.4 years) from 12 countries, 1,619 (80.8%) patients received mood stabilizers, 1,644 (82.14%) received antipsychotics, and 424 (21.2%) received antidepressants, with 14.7% mood stabilizer monotherapy, 13.4% antipsychotic monotherapy, 48.9% simple polypharmacy, 20.3% complex polypharmacy, and 2.6% other therapy. The average psychotropic drug load was 2.05 ± 1.40. Results varied widely between countries.
Conclusion
Over 70% of psychotropic regimens involved polypharmacy, which accords with the high prevalence of polypharmacy in BD under a permissive criterion (2 or more core psychotropic drugs) worldwide. Notably, ≥ 80% of our sample received antipsychotics, which may indicate an increasing trend in antipsychotic use for BD treatment.
4.Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
Ji Min LEE ; Shu-Chen WEI ; Kang-Moon LEE ; Byong Duk YE ; Ren MAO ; Hyun-Soo KIM ; Soo Jung PARK ; Sang Hyoung PARK ; Eun Hye OH ; Jong Pil IM ; Byung Ik JANG ; Dae Bum KIM ; Ken TAKEUCHI
Gut and Liver 2022;16(3):396-403
Background/Aims:
Little is known about the clinical course of hepatitis B virus (HBV)-infected patients undergoing anti-tumor necrosis factor α (TNF-α) therapy for inflammatory bowel disease (IBD). We aimed to investigate the clinical course of HBV infection and IBD and to analyze liver dysfunction risks in patients undergoing anti-TNF-α therapy.
Methods:
This retrospective multinational study involved multiple centers in Korea, China, Tai-wan, and Japan. We enrolled IBD patients with chronic or resolved HBV infection, who received anti-TNF-α therapy. The patients’ medical records were reviewed, and data were collected using a web-based case report form.
Results:
Overall, 191 patients (77 ulcerative colitis and 114 Crohn’s disease) were included, 28.3% of whom received prophylactic antivirals. During a median follow-up duration of 32.4 months, 7.3% of patients experienced liver dysfunction due to HBV reactivation. Among patients with chronic HBV infection, the proportion experiencing liver dysfunction was significantly higher in the non-prophylaxis group (26% vs 8%, p=0.02). Liver dysfunction occurred in one patient with resolved HBV infection. Antiviral prophylaxis was independently associated with an 84% reduction in liver dysfunction risk in patients with chronic HBV infection (odds ratio, 0.16; 95% confidence interval, 0.04 to 0.66; p=0.01). The clinical course of IBD was not associated with liver dysfunction or the administration of antiviral prophylaxis.
Conclusions
Liver dysfunction due to HBV reactivation can occur in HBV-infected IBD patients treated with anti-TNF-α agents. Careful monitoring is needed in these patients, and antivirals should be administered, especially to those with chronic HBV infection.
5.Asian Conference on Tumor Ablation Guidelines for Adrenal Tumor Ablation
Byung Kwan PARK ; Masashi FUJIMORI ; Shu-Huei SHEN ; Uei PUA
Endocrinology and Metabolism 2021;36(3):553-563
Thermal ablation is a good alternative treatment in patients who are unable to undergo adrenalectomy. Even though the Asian Conference on Tumor Ablation (ACTA) has been held for many years, adrenal ablation guidelines have not been established. No guidelines for adrenal ablation are established in American and European countries, either. The aim of this review was to introduce the first version of ACTA guidelines for adrenal tumor ablation.
6.Role of gut microbiota in identification of novel TCM-derived active metabolites.
Tzu-Lung LIN ; Chia-Chen LU ; Wei-Fan LAI ; Ting-Shu WU ; Jang-Jih LU ; Young-Mao CHEN ; Chi-Meng TZENG ; Hong-Tao LIU ; Hong WEI ; Hsin-Chih LAI
Protein & Cell 2021;12(5):394-410
Traditional Chinese Medicine (TCM) has been extensively used to ameliorate diseases in Asia for over thousands of years. However, owing to a lack of formal scientific validation, the absence of information regarding the mechanisms underlying TCMs restricts their application. After oral administration, TCM herbal ingredients frequently are not directly absorbed by the host, but rather enter the intestine to be transformed by gut microbiota. The gut microbiota is a microbial community living in animal intestines, and functions to maintain host homeostasis and health. Increasing evidences indicate that TCM herbs closely affect gut microbiota composition, which is associated with the conversion of herbal components into active metabolites. These may significantly affect the therapeutic activity of TCMs. Microbiota analyses, in conjunction with modern multiomics platforms, can together identify novel functional metabolites and form the basis of future TCM research.
7.Asian Conference on Tumor Ablation Guidelines for Adrenal Tumor Ablation
Byung Kwan PARK ; Masashi FUJIMORI ; Shu-Huei SHEN ; Uei PUA
Endocrinology and Metabolism 2021;36(3):553-563
Thermal ablation is a good alternative treatment in patients who are unable to undergo adrenalectomy. Even though the Asian Conference on Tumor Ablation (ACTA) has been held for many years, adrenal ablation guidelines have not been established. No guidelines for adrenal ablation are established in American and European countries, either. The aim of this review was to introduce the first version of ACTA guidelines for adrenal tumor ablation.
10.Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
Choon Jin OOI ; Ida HILMI ; Rupa BANERJEE ; Sai Wei CHUAH ; Siew Chien NG ; Shu Chen WEI ; Govind K MAKHARIA ; Pises PISESPONGSA ; Min Hu CHEN ; Zhi Hua RAN ; Byong Duk YE ; Dong Il PARK ; Khoon Lin LING ; David ONG ; Vineet AHUJA ; Khean Lee GOH ; Jose SOLLANO ; Wee Chian LIM ; Wai Keung LEUNG ; Raja Affendi Raja ALI ; Deng Chyang WU ; Evan ONG ; Nazri MUSTAFFA ; Julajak LIMSRIVILAI ; Tadakazu HISAMATSU ; Suk Kyun YANG ; Qin OUYANG ; Richard GEARY ; Janaka H DE SILVA ; Rungsun RERKNIMITR ; Marcellus SIMADIBRATA ; Murdani ABDULLAH ; Rupert WL LEONG ;
Intestinal Research 2019;17(3):285-310
The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in the conjunction with conventional treatments for ulcerative colitis (UC) and Crohn's disease (CD) in Asia. These statements also address how pharmacogenetics influence the treatments of UC and CD and provide guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of IBD workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge.
Adalimumab
;
Asia
;
Asian Continental Ancestry Group
;
Biological Factors
;
Biosimilar Pharmaceuticals
;
Colitis
;
Colitis, Ulcerative
;
Consensus
;
Cooperative Behavior
;
Crohn Disease
;
Gastroenterology
;
Hepatitis B
;
Humans
;
Immunologic Factors
;
Inflammatory Bowel Diseases
;
Infliximab
;
Pharmacogenetics
;
Philippines
;
Practice Guidelines as Topic
;
Tuberculosis
;
Ulcer

Result Analysis
Print
Save
E-mail